Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.

Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

New dermoscopic criteria accurately diagnose and grade the severity of hair loss in androgenetic alopecia.

Men with systemic lupus erythematosus often have more severe symptoms but can respond well to treatment.

Plaquenil can cause a severe skin reaction called AGEP, requiring prompt diagnosis and treatment.

Black patients with discoid lupus erythematosus have more severe skin damage and higher chances of dyspigmentation, scalp, and ear involvement.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

The CWARTS tool is a promising method for assessing warts and could improve treatment and research.

Combination therapy may be more effective for difficult-to-treat scalp conditions.

The document concludes that AFA should be considered in patients with acromegaly-like features but normal hormone levels, and more cases need to be identified to understand the condition fully.

Early diagnosis and lifelong zinc supplementation are crucial for treating acrodermatitis enteropathica effectively.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

ERULUS is crucial for root hair growth by controlling calcium levels.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Erosive pustular dermatosis of the scalp may not be as rare as previously thought.

Eczema patients have a lower skin lipid to protein ratio, older and longer-staying hospital patients are more likely to get pressure ulcers, hair loss in AGA is linked to muscle degeneration, vitamin D deficiency is common in alopecia areata and linked to its severity, standard liver tests don't effectively detect fibrosis in psoriasis patients on methotrexate, and bullous pemphigoid patients have a higher death risk but combination therapy may reduce it.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

A multidisciplinary approach is essential for effectively managing cutaneous lupus erythematosus.

A rare skin condition causes red, dark, bumpy facial lesions.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

EPDS is a rare, chronic scalp condition that's hard to treat and needs better awareness for improved outcomes.

AHR ligands could treat inflammatory skin diseases.

The Excimer Laser effectively treats alopecia areata, and dermoscopy helps assess treatment response.